Novo Nordisk A/S
NVO
USReal-Time PriceNovo Nordisk A/S (NVO) Stock News
The latest Novo Nordisk A/S (NVO) news in one feed: earnings updates, analyst ratings, product launches and regulatory filings, curated and summarized by BTI.
Lilly's Obesity Pill Gains Traction as Chip Stocks Attempt a Rebound
A Bank of America physician survey suggests Lilly's oral obesity drug is expanding the GLP-1 market rather than merely shifting existing patients, while a fragile semiconductor rebound shows risk appetite remains unsettled.
Lilly’s Foundayo Clears an EU Hurdle, but Approval Is Not Final
The EMA’s medicines committee recommended Foundayo for obesity and type 2 diabetes. European Commission approval and national reimbursement decisions still stand between Lilly and broad commercial access.
Walmart Expands No-Cost Drug Coverage for 1.6 Million U.S. Workers
Walmart will add more than 250 no-cost prescriptions and cover selected diabetes GLP-1 drugs in 2027, using richer benefits to compete for workers while limiting weight-loss exposure.
Novo Nordisk’s Stable-Margin Plan Makes Revenue Mix More Important
Citi cut Novo Nordisk’s target to DKK 296 as management projected stable margins. Oral Wegovy may lift sales while R&D and capacity spending absorb leverage.
Eli Lilly Drops 8% in a Month, but Citi Sees 45% Upside to $1,600
Eli Lilly has fallen more than 8% in a month even as Q2 revenue grew 48% and full-year guidance increased. Citi’s $1,600 target rests on GLP-1 leadership, new oral products and a deep late-stage pipeline.
Morgan Stanley Turns Bearish on Novo Nordisk as Semaglutide Concentration Becomes a Valuation Risk
Morgan Stanley downgraded Novo Nordisk as semaglutide dominates sales and major patents approach expiry in the early 2030s. The obesity market remains enormous, but pipeline diversification now matters more than category growth alone.